This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


SALCITAL Benefits Pre-Diabetes Management, Hyperlipidemia

BANGALORE, India—SALCITAL by Olive Lifesciences may benefit pre-diabetes management and mild to moderate hyperlipidemia, according to a study published in the Journal of Medicinal Food (June 2013, 16(6): 564-568. DOI:10.1089/jmf.2013.2751).

 The randomized, double blind, placebo-controlled study evaluated the efficacy and safety of Salacia leaves and root bark extracts in 29 subjects with pre-diabetes and mild to moderate hyperlipidemia. Subjects received either Salacia extracts or placebos, along with therapeutic lifestyle changes, for a period of six weeks. Researchers observed a significant reduction in low-density lipoprotein (LDL) cholesterol and fasting blood sugar (FBS) levels at weeks three and six in patients treated with root bark extract. The leaves extract-treated group showed statistically significant reduction in FBS levels at week six only.

Apart from its nutraceutical application, SALCITAL is also applicable as dry drink mixes, ready-to-drink (RTD) products, nutritional bars and other beverages, according to C.A. Anzar, managing director of Olive Lifesciences.

Olive Lifesciences also recently launched websites for its ingredients BioTurmin and MaQxan.

comments powered by Disqus